3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
6
Completed
3
Recruiting
2
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Ameloblastoma
1
Interventions
Dexamethasone
16
daratumumab
14
Bortezomib
11
Lenalidomide
9
pomalidomide
7
Calcium Dobesilate
6
isatuximab
4
belantamab mafodotin
4
Cyclophosphamide
4
carfilzomib
3
Melphalan
3
tocilizumab
2
iberdomide
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
auricularum
2
Specimen Handling
2
Maintenance
2
Injections
2
Immunotherapy, Adoptive
2
Exercise Therapy
2
Drug Therapy
2
CT103A chimeric antigen receptor
2
Biopsy
2
zanubrutinib
1
trametinib
1
talquetamab
1
selinexor
1
pembrolizumab
1
ixazomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Multiple Myeloma
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled